Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04749563 | Study of IGC-AD1 in Subjects With Dementia Due to Alzheimer's Disease | PHASE1 | COMPLETED | 12 | — | — | Jan 11, 2021 | Jun 20, 2021 | Sep 16, 2022 | 1 | Puerto Rico |
Evaluate safety and tolerability of IGC AD1 10 participants will be administered the investigational drug and two will be administered placebo. Incidence of treatment emergent adverse events will be assessed to determine safety and tolerability of IGC-AD1.
| Arm | Type | Description |
|---|---|---|
| Active | ACTIVE_COMPARATOR | IGC AD1 |
| Placebo | PLACEBO_COMPARATOR | IGC AD1 Placebo |
| Name | Type | Description |
|---|---|---|
| IGC AD1 | DRUG | IGC AD1 oral Solution |
| Placebo | DRUG | Placebo of IGC AD1 oral Solution |
Inclusion Criteria: 1. Patient and/or study partner (relative) must provide a signed and dated Informed Consent form prior to any study procedures which will be discussed with the Study Coordinator. 2. Provision of a letter from the Neurologist/Psychiatrist/Internal Medicine Physician certifying th...